search
Back to results

Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

Primary Purpose

Inflammation, Infection

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin D3 Supplementation
Sponsored by
Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Inflammation focused on measuring Vitamin D, Pregnancy, Inflammation, Infection, Placenta, Cytokine, Microbiome

Eligibility Criteria

13 Years - 18 Years (Child, Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female adolescents between 13 and 18 years of age
  • Between 12 and < 30 weeks pregnant

Exclusion Criteria:

  • HIV-infection
  • Eating disorders
  • Malabsorption diseases
  • Diabetes mellitus
  • Gestational diabetes
  • Pregnancy induced hypertension or elevated diastolic blood pressure (>110)
  • Steroid use
  • Substance abuse history
  • Taking medications known to influence Ca or vitamin D status
  • Diagnosis of elevated blood lead concentrations during childhood
  • Smokes tobacco

Sites / Locations

  • Highland Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

200 IU Vitamin D3

2000 IU Vitamin D3

Arm Description

A singular daily dose of 200 IU vitamin D3

A singular daily dose of 2000 IU vitamin D3

Outcomes

Primary Outcome Measures

Change in Vitamin D status, infections and inflammation across pregnancy after Vitamin D supplementation
Maternal calciotropic hormones (25(OH)D, 1,25(OH)2D, 24,25(OH)2D, and PTH) and inflammatory cytokines (CRP, interleukin [IL]-6 and IL-10 and tumor necrosis factor [TNF]-alpha) will be measured at entry into the study and again at 23-28 weeks gestation and delivery after treatment with 200 IU or 2000 IU D3/d. These measures will be compared to inflammatory processes and infections reported in medical records across pregnancy.

Secondary Outcome Measures

Change in maternal vitamin D status and inflammatory markers in serum
In a retrospective analysis, inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) in archived serum collected from a cohort of 158 adolescents that were longitudinally followed across pregnancy both at mid-gestation and at delivery will be related to 25-hydroxyvitamin D (25(OH)D), 1,25- dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone (PTH) and medically treated infections and inflammatory conditions abstracted from medical records.
Association of maternal vitamin D status (25(OH)D concentration with longitudinal change in 1,25(OH)2D, PTH, 24,25(OH)2D,and the vitamin D metabolite ratio

Full Information

First Posted
March 11, 2013
Last Updated
October 25, 2019
Sponsor
Cornell University
Collaborators
University of Rochester
search

1. Study Identification

Unique Protocol Identification Number
NCT01815047
Brief Title
Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy
Official Title
Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
May 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cornell University
Collaborators
University of Rochester

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this study is to characterize the function and efficacy of the bioactive nutrient, vitamin D, in relation to infection and inflammatory status across pregnancy. The three specific aims of this study are 1) To address the impact of maternal vitamin D status on inflammation and infections across pregnancy using retrospective data, 2) To address the impact of vitamin D supplementation on maternal vitamin D status, inflammation and infections across pregnancy using prospective data and 3) To assess the impact of maternal vitamin D status during pregnancy on inflammatory mediators at the level of the placenta.
Detailed Description
Archived serum collected from 158 adolescents at mid-gestation (approximately 26 weeks) and delivery will be analyzed for inflammatory cytokines. The impact of these inflammatory markers will be assessed by comparing the data to measures of vitamin D (25(OH)D, calcitriol and parathyroid hormone) and infections and inflammatory complications abstracted from medical charts. Placental samples were collected from a subset (n=132) of these pregnant teens and these tissues will be analyzed using genome wide microarray of messenger ribonucleic acid (mRNA) and microRNA (miRNA) related to inflammatory processes. A separate group of pregnant adolescents (n=140) will be recruited at entry into prenatal care for a vitamin D supplementation trial. Teens will be randomly assigned to one of two supplements (200 IU D3/d vs. 2000 IU D3/d). Similar to the retrospective analysis, maternal calciotropic hormones and inflammatory cytokines will be assessed at entry into the study, mid-gestation (23-28 weeks) and at delivery. Inflammatory processes and infections reported across pregnancy will be evaluated in relation to vitamin D status and inflammatory markers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Inflammation, Infection
Keywords
Vitamin D, Pregnancy, Inflammation, Infection, Placenta, Cytokine, Microbiome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
85 (Actual)

8. Arms, Groups, and Interventions

Arm Title
200 IU Vitamin D3
Arm Type
Experimental
Arm Description
A singular daily dose of 200 IU vitamin D3
Arm Title
2000 IU Vitamin D3
Arm Type
Experimental
Arm Description
A singular daily dose of 2000 IU vitamin D3
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3 Supplementation
Primary Outcome Measure Information:
Title
Change in Vitamin D status, infections and inflammation across pregnancy after Vitamin D supplementation
Description
Maternal calciotropic hormones (25(OH)D, 1,25(OH)2D, 24,25(OH)2D, and PTH) and inflammatory cytokines (CRP, interleukin [IL]-6 and IL-10 and tumor necrosis factor [TNF]-alpha) will be measured at entry into the study and again at 23-28 weeks gestation and delivery after treatment with 200 IU or 2000 IU D3/d. These measures will be compared to inflammatory processes and infections reported in medical records across pregnancy.
Time Frame
Entry into study, mid-gestation and delivery
Secondary Outcome Measure Information:
Title
Change in maternal vitamin D status and inflammatory markers in serum
Description
In a retrospective analysis, inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) in archived serum collected from a cohort of 158 adolescents that were longitudinally followed across pregnancy both at mid-gestation and at delivery will be related to 25-hydroxyvitamin D (25(OH)D), 1,25- dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone (PTH) and medically treated infections and inflammatory conditions abstracted from medical records.
Time Frame
Mid-gestation and delivery
Title
Association of maternal vitamin D status (25(OH)D concentration with longitudinal change in 1,25(OH)2D, PTH, 24,25(OH)2D,and the vitamin D metabolite ratio
Time Frame
Mid-gestation and delivery
Other Pre-specified Outcome Measures:
Title
Vitamin D and placental inflammation
Description
Genome-wide microarray studies of mRNA and miRNA in a subset of placental tissue from adolescents with insufficient (<15 ng/mL) and sufficient vitamin D status (>30 ng/mL) will be screened for differential regulation of genes and gene networks involved in inflammatory processes.
Time Frame
Delivery
Title
Vaginal microbiome profile
Description
Vitamin D supplementation (200 IU/d D3 and 2000 IU/d D3), dietary intake, 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25 (OH)2D), parathyroid hormone(PTH), inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) and infection (from medical records) will be related to vaginal microbiome profile.
Time Frame
Mid to late gestation

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female adolescents between 13 and 18 years of age Between 12 and < 30 weeks pregnant Exclusion Criteria: HIV-infection Eating disorders Malabsorption diseases Diabetes mellitus Gestational diabetes Pregnancy induced hypertension or elevated diastolic blood pressure (>110) Steroid use Substance abuse history Taking medications known to influence Ca or vitamin D status Diagnosis of elevated blood lead concentrations during childhood Smokes tobacco
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kimberly O'Brien, PhD
Organizational Affiliation
Cornell University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Highland Hospital
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
29796622
Citation
Best CM, Pressman EK, Queenan RA, Cooper E, Vermeylen F, O'Brien KO. Gestational Age and Maternal Serum 25-hydroxyvitamin D Concentration Interact to Affect the 24,25-dihydroxyvitamin D Concentration in Pregnant Adolescents. J Nutr. 2018 Jun 1;148(6):868-875. doi: 10.1093/jn/nxy043.
Results Reference
derived

Learn more about this trial

Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

We'll reach out to this number within 24 hrs